Pfizer Strikes USD 2.6 Billion Deal With China's Starna Therapeutics for CAR-T Autoimmune Therapies
Pfizer has agreed to pay $330 million upfront and up to $2.3 billion more for three autoimmune therapies from Starna Therapeutics, pending milestones. The deal focuses on in vivo CAR-T therapies, with Pfizer handling development and commercialization outside Greater China. This follows Pfizer's recent deals with Innovent Biologics and 3SBio.
How this was made

The 30-second read
Why it matters
The $330 million upfront and up‑to‑$2.3 billion in milestones represent a significant capital commitment, likely to be reflected in Pfizer's stock valuation.
Market read
A major M&A‑type partnership that could reshape Pfizer's growth trajectory and influence biotech sector sentiment.
What to watch
Potential integration challenges and reliance on Starna's early‑stage assets may limit near‑term upside.
Background
Pfizer is preparing for a wave of patent expirations and declining COVID‑related revenue, prompting strategic deals to replenish its pipeline.
Ticker impact
Pfizer announced a $2.6 billion deal with China's Starna Therapeutics for CAR‑T autoimmune therapies.
upward pressure as the market prices in the growth potential of the new CAR‑T programs.
Large-scale partnership with upfront cash and milestone payments indicates material future revenue and strategic diversification.
Market effects
Strengthens the biotech/immune‑therapy sector as big pharma backs CAR‑T platforms.
Highlights growing US‑China biotech collaborations despite geopolitical tensions.
Adds to the narrative of large pharma seeking growth through innovative cell therapies.
Counterpoint
If regulatory hurdles delay CAR‑T approvals, the deal could become a financial drag.
Key entities
- CompanyPfizer
US‑listed pharmaceutical giant (ticker PFE).
- CompanyStarna Therapeutics
Chinese biotech partner developing CAR‑T autoimmune therapies.




